GSK547
CAS No. : 2226735-55-1
(Synonyms: GSK'547)
| Size | Price | Stock |
|---|---|---|
| 5mg | $120 | In-stock |
| 10mg | $190 | In-stock |
| 25mg | $350 | In-stock |
| 50mg | $550 | In-stock |
| 100mg | $750 | In-stock |
| 200mg | $975 | In-stock |
| 500 mg | Get quote | |
| 1 g | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-114492 |
| M.Wt: | 396.39 |
| Formula: | C20H18F2N6O |
| Purity: | >98 % |
| Solubility: | DMSO : 250 mg/mL (ultrasonic) |
GSK547 (GSK'547) is a highly selective and potent inhibitor of receptor-interacting serine/threonine protein kinase 1 (RIPK1), inhibits macrophage-mediated adaptive immune tolerance in pancreatic cancer[1].
IC50 & Target: RIP1[1]
In Vitro: GSK547 (0.1-100000 nM; 24 hours) pretreats L929 cells with recombinant TNFα and zVAD at various doses for 30 min, then cell death is induced with an IC50 of 32 nM after 24 hours[1].
GSK547 up-regulates STAT1 signaling in bone marrow-derived macrophages (BMDM)[1].
In Vivo: GSK547 (GSK′547; RIP1i) robustly targets RIP1 in vivo. RIP1 inhibition results in immunogenic macrophage differentiation in pancreatic cancer, leading to adaptive immune activation and tumor protection for pancreatic ductal adenocarcinoma (PDA)[1].
GSK547 (100 mg/kg/day; fed via food-based dosing; 15-50 days) reduces tumor burden and extends survival compared with mice treated with controls or Nec-1s[1].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- GSK547
- Cat. No.:
- HY-114492
- Quantity:
Your information is safe with us.